14028(14028) - _专利_临床

概要

基本信息

药物类型

重组多肽、生物类似药

别名-

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

2型糖尿病

原研机构

东莞市东阳光生物药研发有限公司

在研机构-

非在研机构

东莞市东阳光生物药研发有限公司

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

2

项与 14028 相关的临床试验

NCT05459285 / Completed临床1期

Pharmacokinetics, Safety and Immunogenicity of 14028 Injection Versus Dulaglutide Injection in Healthy Subjects: a Phase I ，Single-center, Randomized, Open-label, Single-dose, Parallel-controlled Clinical Study

To evaluate the pharmacokinetics similarity between the 14028 injection produced by Sunshine Lake Pharma Co., Ltd. and dulaglutide injection (TRULICITY®) produced by Eli Lilly and Company for single dose in healthy male subjects, as well as to evaluate the similarity of the safety and immunogenicity between 14028 Injection and TRULICITY® in Healthy Subjects

开始日期2022-05-31

申办/合作机构